404 results about "Virus Protein" patented technology

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and / or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A / Sydney / 5 / 94 (H3N2) and / or avian influenza virus type A / Hong Kong / 1073 / 99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

A flexible automated apparatus for isolating and purifying viruses, proteins and peptides of interest from a plant material is disclosed, the apparatus being applicable for large scale purification and isolation of such substances from plant material. The flexible automated apparatus provides an efficient apparatus for isolating viruses, proteins and peptides of interest with little waste material. The automated apparatus for isolating viruses, proteins and peptides of interest includes a grinding apparatus for homogenizing a plant to produce a green juice, a means for adjusting the pH of and heating the green juice, a means for separating the target species, either virus or protein / peptide, from other components of the green juice by one or more cycles of centrifugation, resuspension, and ultrafiltration, and finally purifying virus particles by such procedure as PEG-precipitation or purifying proteins and peptides by such procedures as chromatography and / or salt precipitation.

The present invention relates to immunogenic but non-depositing-forming polypeptides or peptides homologous to amyloid β, prion, amylin or α-synuclein which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid β peptides and amyloid deposits, to prion protein and prion deposits, to amylin and amylin deposits, to α-synuclein and deposits containing α-synuclein, or to polyglutamine repeats and deposits of proteins containing polyglutamine repeats. Described are also antibodies directed against such peptides, their generation, and their use in methods of passive immunization to such peptides and deposits.

The present invention discloses and claims virus like particles (VLPs) that express and / or contains seasonal influenza virus proteins, avian influenza virus proteins and / or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

Disclosed herein are compositions and methods for imaging nerve cells. The composition comprises a fluorescent dye; and a viral component selected from a neurotropic, replication-defective virus, a viral protein of a neurotropic virus, and a capsid of a neurotropic virus. Although the fluorescent dye in itself cannot penetrate nerve cells, the fluorescent dye is bound to the viral component to form a dye / viral component complex that is capable of penetrating nerve cells.

The invention relates to 'a blood DNA preserving card and production method' and belongs to the biology technical field. A blood DNA preserving card comprises fiber-shaped media with the ability of absorbing DNA, and is characterized in that: the salinity is absorbed in the media and contains cell lysing reagent, nuclease inhibitor, a substance allowing the pathogenic bacterium and the virus protein to be denaturalized as well as anti-oxidization inhibitor. These salinities can inhibit the activities of the viruses to prevent the infection, can prevent the nuclease from gradating DNA, so that the blood DNA can be preserved indoor for a long-term. The pure DNA can be obtained from the preserved DNA in the card of the invention by bleaching the salt ions and blood corpuscle leftovers on the card media with the water, thereby avoiding the extraction process, ensuring the operation is simpler, being convenient to be operated in batches and saving the expense of the DNA extraction agent.

The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacterial proteins, viral proteins, cancer cells, and proteins or toxins produced therefrom. In particular, the present invention includes methods and systems for binding agents that are specific to neurotoxins that cause botulism.

The invention relates to an enzyme-linked immunosorbent assay (ELISA) kit for duck hepatitis virus type-I serum antibody and relates to a test method and application of the kit. The kit comprises an enzyme label plate coated by the recombinant VP1 (virus protein) protein, a rabbit anti-duck IgY antibody marked by horseradish peroxidase, a TMB substrate colour reagent, a positive serum, a negative serum and a kit specification. In the invention, by adopting the polymerase chain reaction, the VP1 genes are amplified from the DHV-1genome and the VP1 gene-containing recombinant expression plasmid pET32a-VP1 is constructed; the plasmid is transferred to host cells BL21 (DE3), and the in-vitro expression VP1 protein is purified by a nickel column and then used as the antigen; the enzyme-linked immunosorbent assay kit is established; the positive serum is the standard positive serum of duck hepatitis virus type-I and the negative control is the standard negative serum of duck. The test kit has the advantages of strong specificity, high sensitivity, simple operation, easy large-scale popularization and application, very important application value in diagnosis of duck hepatitis virus type-I, survey of epidemiology and immunization survey and the like.

The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present invention relates methods of generating infectious recombinant negative-strand RNA viruses intracellularly in the absence of helper virus from expression vectors comprising cDNAs encoding the viral proteins necessary to form ribonucleoprotein complexes (RNPs) and expression vectors comprising cDNA for genomic viral RNA(s) (vRNAs) or the corresponding cRNA(s). The present invention also relates to methods of generating infectious recombinant negative-strand RNA viruses which have mutations in viral genes and / or which express, package and / or present peptides or polypeptides encoded by heterologous nucleic acid sequences. The present invention further relates the use of the recombinant negative-strand RNA viruses or chimeric negative-strand RNA viruses of the invention in vaccine formulations and pharmaceutical compositions.

The invention provides a polypeptide capable of being applied to 2019 novel coronavirus (SARS-CoV-2) detection and antibody or vaccine drug screening. The polypeptide comprises at least 15 continuousamino acid sequences in an S protein sequence, an N protein sequence or an orf1ab protein sequence of an SARS-CoV-2 virus protein, and comprises any amino acid sequence as shown in SEQ ID No.1 to 25.

The invention discloses a preparing method for a tobacco mosaic virus nanowire composite material with the surface functionalized. The preparing method includes the following steps that while tobacco mosaic virus head-tail assembly is carried out on the acidic condition, dopamine and an oxidant are subjected to in-situ oxidative polymerization on the outer surface of virus protein to form tobacco mosaic virus nanowires coated with polydopamine, and on the alkaline condition, the own reducibility and reactivity of the surface polydopamine are used for further loading gold nanoparticles and modifying bioactive molecules containing amino groups or sulfydryl groups in a functionalized mode without extra reductant or chemical modification so as to obtain the tobacco mosaic virus nanowire composite material with the surface functionalized. The preparing method has the advantages of being simple in process, convenient, efficient and capable of being widely applied to biological catalysis, biological imaging, tumor targeted probes, nano-drug carriers and other fields of biomedical new nano materials.

The invention provides a kit for detecting a peste des petits ruminants virus hemagglutinin protein (H protein) antibody. The kit takes recombinant protein of extracellular region sequence code of peste des petits ruminants virus hemagglutinin protein gene as an envelope antigen. The invention further provides an application method of the kit. The kit can quickly specifically detect the peste des petits ruminants virus H protein antibody in serum, and is good in reaction specificity and high in sensitivity. The operation is simple; the cost is low; and the reaction result is stable and reliable, and is easy to observe. The kit is suitable for monitoring the vaccine immunity effect of import and export immunity, food sanitation, and a livestock farm of peste des petits ruminants.

A method for separating microorganisms, especially infectious agents, from a mixture by two dimensional centrifugation on the basis of sedimentation rate and isopycnic banding density, for sedimenting such microorganisms through zones of immobilized reagents to which they are resistant, for detecting banded particles by light scatter or fluorescence using nucleic acid specific dyes, and for recovering the banded particles in very small volumes for characterization by mass spectrometry of viral protein subunits and intact viral particles, and by fluorescence flow cytometric determination of both nucleic acid mass and the masses of fragments produced by restriction enzymes. The method is based on the discovery that individual microorganisms, such as bacterial and viral species, are each physically relatively homogeneous, and are distinguishable in their biophysical properties from other biological particles, and from non-biological particles found in nature. The method is useful for distinguishing infections, for identifying known microorganisms, and for discovering and characterizing new microorganisms. The method provides very rapid identification of microorganisms, and hence allows a rational choice of therapy for identified infectious agents. A particularly useful application is in clinical trials of new antibiotics and antivirals, where it is essential to identify at the outset individuals infected with the targeted infectious agent.

The invention discloses an immunochromatographic kit used for detecting novel coronavirus SARS-CoV-2 infection. The kit comprises a test strip. The test strip comprises a sample pad, a combination pad, a chromatography membrane and an absorption pad which are correspondingly pasted and laminated, and the combination pad is coated with a colloidal gold labeled neopterin antibody conjugate, a novelcoronavirus N protein conjugate, a novel coronavirus S1 protein conjugate and a DNP-BSA conjugate. A quality control line C and a detection line are arranged on the NC membrane. The C line is coated with a rabbit anti-DNP antibody, the detection line comprises a T1 line, a T2 line and a T3 line. The T1 line and the T2 line are respectively coated with one of an anti-human IgG antibody and an anti-human IgM antibody. The T3 line is coated with a Neo-BSA antigen, and the C line, the T1 line and the T2 line are three parallel bands perpendicular to the long side of the test strip. The kit provided by the invention is beneficial to early diagnosis and rapid confirmation of novel coronavirus infection, and has high sensitivity.

The invention relates to a recombinant nerve putrescence virus protein vaccine, the nucleic acid sequence coding the recombinant protein, and the use of the recombinant protein in preparing fish use vaccine product for nerve putrescence viruses resistance. Wherein the cDNA of the capsid nucleocapsid for the grouper nerve putrescence viruses is utilized to obtain the polypeptide recombinant proteins through DNA recombination process and pronucleus expression method.

The present invention relates to a novel Ad based packaging system that can be used for incorporation of heterologous DNA into infectious but replication defective viral particles. The components of the invention include an “artificial genome”, i.e., a recombinant vector which contains elements that function as adenovirus replication and packaging signals flanking an intervening DNA sequence. The elements may comprise the minimum genomic Ad sequences required to direct replication of heterologous DNA and packaging into viral particles. The system also includes a means for expressing complementing helper functions to provide in trans viral proteins required for replication and packaging of recombinant viral vectors, but without contaminating the stock of recombinant, trans-packaged viral particles.

The invention discloses two types of ScFv (Single Chain Variable Fragment) antibodies, encoding genes of the antibodies and applications of the antibodies for preparing the preparations for treating or preventing infectious bursal disease of chicken. Two single-chain antibodies (namely, the ScFv antibodies) are provided; and the ScFv antibodies can be specially bound with the protein 2 (VP2) (Virus Protein 2) in an IBDV (Infectious Bursal Disease Virus) structure and a plurality of IBDV strains to block the cytopathic effect (CPE) of the chicken embryo fibroblast by the IBDV so as to protect the young chicken infected with IBDV. The immune serum and egg yolk antibody are tedious in preparation, high in production cost, unstable in effect, difficult to control industrialized production quality, capable of causing horizontal disease spread and the like in a use process; the ScFv antibodies disclosed by the invention can overcome the above disadvantages and have the advantages of strong specificity, good treatment effect, controllable industrialized production quality, capability of preventing the horizontal disease spread caused by the egg yolk antibody and the like; and therefore, by virtue of the ScFv antibodies, a new situation is opened up in the IBDV prevention and treatment history, and even in the entire prevention and treatment history for animal virus diseases.

This invention belongs to molecule biology and biomedicine technique field. It relates to 9 target points of RNA disturbing to HBV and applications of preparing hepatitis B medicine according to these target sequence. Plasmid is expressed through shRNA and siRNA transfection cell and animal cell is chemical synthesized. Then 16 RNA target point on HBV tissue is sieved, 9 of them can obvious restrain HBV protein expression at cell level. Expression and virus duplication of HBV protein inside cell can be stably restrained by 11 target point, and expression of HBV transgene little mouse in vivo virus protein can be restrained. Medicine curing hepatitis B can be made according to these target sequence.

The invention relates to a method for preparing a recombining spore of surface display foreign protein, in particular to a recombining spore for surface display prawn white spot syndrome virus Vp28 protein of a bacillus subtilis spore. In the method, a bacillus subtilis spore capsid protein gene is used as a molecule vector and is recombined with an antigen protein gene on the surface of the prawn white spot syndrome virus to construct an integral recombining plasmid in fusion expression; the bacillus subtilis is converted to a bacillus subtilis recombining strain; and the recombining spore of the spore surface display prawn white spot syndrome virus protein produced by the recombining strain is induced.

The invention discloses monoclonal antibody of anti-dengue virus E protein, which is generated through the secretion of the mice hybridoma cells 2B10 with the collection number of CGMCC No.2407; the monoclonal antibody provided by the invention has the advantages that the comprehensive effectiveness is high, the monoclonal antibody can be specifically combined with the dengue virus and can be applied to the preparation of the novel and effective medicine which can prevent and cure dengue virus infection and can also be manufactured into reagent kits for testing dengue virus.

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.

The invention discloses a mycobacterium tuberculosis TB10.4-F1 fusion protein vaccine and a preparation method thereof. The preparation method comprises the following steps of: connecting the mycobacterium tuberculosis TB10.4 protein gene with the F1 protein gene of respiratory syncytial virus protein, transferring into a colibacillus expressing strain, inducing by IPTG (isopropyl beta-D-1-thiogalactopyranoside) to express the TB10.4-F1 fusion protein, and acquiring the protein with higher purity by metal ion affinity chromatography. The fusion protein has stronger immunogenicity, can excite more balanced Th1 / Th2 immune response, and can prevent infections of the mycobacterium tuberculosis and the respiratory syncytial virus.

The invention discloses a peste des petits ruminants virus recombinant protein antigen and a rapid test strip for detecting a peste des petits ruminants virus antibody by using the recombinant protein antigen as a detection line reagent. The peste des petits ruminants virus recombinant protein antigen can be obtained by the following steps: selecting main antigenic epitope-containing amino acid segment SEQ IDNo.1 through analyzing the N protein antigenic epitope of the peste des petits ruminants virus, optimizing a codon and artificially synthesizing the codon-optimized gene sequence SEQIDNo.2, constructing a recombinant expression carrier and transforming Escherichia coli for protein expression. The purified peste des petits ruminants virus recombinant protein antigen can be used for detecting the peste des petits ruminants virus antibody. The rapid test strip established based on the peste des petits ruminants virus recombinant protein antigen has the advantages of being convenient to operate, fast to detect, free from special laboratories, equipment and the like, overcomes the limit of the existing detection method, and can be used for rapid detection of the peste des petits ruminants virus antibody and investigation of serum epidemiology.